Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Exclusion Criteria

• 1. Receipt of any
• investigational anticancer therapy within 28 days or 5 halflives, whichever is longer, prior to the first dose of study treatment
• 2. Brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment
• 3. Any unresolved Grade ≥2 toxicity from previous anticancer therapy
• 4. Active or prior documented autoimmune or inflammatory disorders
• 5. Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with
• study requirement, substantially increase risk of incurring AEs from study drugs, or compromise the ability of the patient to give written informed consent
• 6. Mean QT interval corrected for heart rate using Fridericia’s formula (QTcF) ≥470 ms 20. Active tuberculosis
• 7. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)